Scientists have had early success in treating patients with cancer by targeting specific immune cells, and a new study showed that some patients could avoid chemotherapy or radiation therapy altogether.
Those who underwent the experimental treatment to battle rectal cancer at the Memorial Sloan Kettering Cancer Center in Manhattan, US, reached remission in six months, according to a study team led by several notable cancer physicians. The experimental cancer therapy showed excellent results, with 12 out of 12 rectal cancer patients seeing disease remission.
The treatment, known as “Dostarlimab” (DS), is a medication that indicts cancer cells so that the immune system can eliminate them.
Patients were given a measurement of Dostarlimab at regular intervals for a long time, with the assumption that they would have to revert to chemotherapy, radiation treatment, and medical procedure. However, specialists found that the disease was destroyed by simply utilizing experimental medicine.
Furthermore, the patients had no noteworthy adverse responses during their therapy, albeit there were not enough patients participating to understand the many adverse reactions that the medicine can induce. Nonetheless, this is an intriguing outcome that requires confirmation before researchers can infer that the findings are permanent.
“This is the first time this has happened in the history of cancer,” said Dr. Luis Diaz, an oncologist at the Memorial Sloan Kettering Cancer Centre in New York.
Cancer is a devastating disease that affects millions of people every year. A cancer cure would have a huge positive impact on society, and this new research is the most promising we’ve seen in decades.